US OptionsDetailed Quotes
CRDL241220C5000
- 0.05
- 0.000.00%
15min DelayClose Nov 29 12:58 ET
0.00High0.00Low
0.05Open0.05Pre Close0 Volume1.61K Open Interest5.00Strike Price0.00Turnover315.06%IV211.73%PremiumDec 20, 2024Expiry Date0.00Intrinsic Value100Multiplier19DDays to Expiry0.05Extrinsic Value100Contract SizeAmericanOptions Type0.1153Delta0.1665Gamma32.40Leverage Ratio-0.0059Theta0.0001Rho3.74Eff Leverage0.0007Vega
Cardiol Therapeutics Stock Discussion
Cardiol Therapeutics' Phase II MAvERIC-Pilot Clinical Results in Recurrent Pericarditis Presented at the American Heart Association Scientific Sessions 2024
Cardiol Therapeutics (NASDAQ: CRDL) reported positive Phase II MAvERIC-Pilot clinical results for CardiolRx™ in treating recurrent pericarditis. The study showed marked improvements in pericarditis pain and inflammation maintained throughout the 26-week study. The trial enrolled 27 participants across eig...
Cardiol Therapeutics Announces Closing of US$13.5 Million Public Offering of Common Shares
Cardiol Therapeutics Achieves Target Patient Enrollment in its Phase II ARCHER Trial Investigating CardiolRx(TM) for Acute Myocarditis
Cardiol Therapeutics (NASDAQ: CRDL) announced the completion of target patient enrollment for its Phase II ARCHER trial, evaluating CardiolRx™ in acute myocarditis. The trial, with 100 patients from five countries, aims to assess the safety, tolerability, and impact of CardiolRx™ on myocardial recovery. Primary outcomes include...
newsfile·
Full clinical data will be reported in an oral presentation at the premier global event for advancements in cardiovascular science and medicine on November 18, 2024
Cardiol Therapeutics Announces Positive Topline Data from its Phase II MAvERIC-Pilot Study Investigating CardiolRx(TM) for Recurrent Pericarditis
Cardiol Therapeutics announced positive topline data from its Phase II MAvERIC-Pilot study, evaluating CardiolRxTM for treating recurrent pericarditis. The 8-week clinical data showed a significant reduction in pericarditis pain and inflammation. The study involved 27 patients, and 89% continued into the extension ph...
Huge Opportunity
💵✈️✈️✈️✈️✈️
NEWS
Cardiol Therapeutics Announces Phase II ARCHER Trial Presented at the World Congress on Acute Heart Failure 2024
Cardiol Therapeutics presented its Phase II ARCHER trial at the World Congress on Acute Heart Failure 2024. The trial is evaluating CardiolRx™ in patients with acute myocarditis. The presentation included the trial design, rationale, and baseline data on the first 50 patients randomized. The ARCHER trial has exceeded 85% of target enrollment, with ...
No comment yet